OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Archiving: full-text archived in CLOCKSS.
Publication Speed (median values for papers published in 2022): Submission to First Decision: 5 weeks; Submission to Acceptance: 14 weeks; Acceptance to Publication: 11 days (1-2 days of FREE language polishing included)
Health Modifiers of Neurocognitive Aging
Submission Deadline: November 30, 2018 (Open) Submit Now
Kamen Tsvetanov, PhD
Centre for Speech, Language and the Brain, Department of Psychology, University of Cambridge, Downing Street, Cambridge CB2 3EB, UK
Research Interests: Ageing; fMRI; neuroscience; connectomics; brain dynamics; cognitive neuroscience of ageing; relationship between human brain dynamics and cognition in healthy ageing and age-degenerative diseases
About This Topic
With the global demographic shift towards an older population, there is a pressing need to maintain mental wellbeing into late life, allowing people to work and live independently for longer. There are many influences on mental health which can be cultural, social, genetic, health and our own lifestyle decisions. These have an effect on our brain, and how well our brain works for what we call cognitive health – good memory, perception, language, judgement and so on.
The purpose of this Special Issue is to compile a number of selected research articles that focus on identifying factors for maintaining neurocognitive function across the lifespan – or ‘health modifiers’ – why some people seem to age without apparent adverse effects on their cognitive abilities, while others fare badly even without a dementia illness. In addition, this Special Issue welcomes review article submissions that critically assess the current knowledge on major health modifiers for mechanisms of neurocognitive aging. Addressing these issues has implications for understanding the influences that promote our brains process information to support mental functioning, throughout adult life.
Received: 30 November 2018; Published: 20 March 2019; doi: 10.21926/obm.geriatr.1901039
Background: While the percent of persons 65 and older is expected to increase to 17% of the world’s population by 2050, this increase in longevity does not necessarily suggest a parallel increase in health status. While aging is an inevitable aspect of living, there are factors which can accelerate morbidity and mortality, as well as factors [...]
25-hydroxyvitamin D Levels are Associated with Cognitive Dysfunction in Type 2 Diabetes and the Metabolic Syndrome: A Preliminary Examination
by Lisa M. Manderino , Mary Beth Spitznagel , Divya Yogi-Morren , John P. Kirwan , Sangeeta Kashyap and John Gunstad
Received: 01 August 2018; Published: 05 December 2018; doi: 10.21926/obm.geriatr.1804023
Background: Type 2 diabetes (T2DM) and metabolic syndrome are linked to pathological changes in the brain and increased likelihood of cognitive impairment. Vitamin D insufficiency is commonly found in this population and is associated with cognitive dysfunction in other patient groups. The present study aims to demonstrate the presence of [...]
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.